FAP in this disease context refers to familial adenomatous polyposis, an autosomal dominant inherited colorectal cancer predisposition syndrome caused mainly by APC pathogenic variants. It leads to development of numerous colorectal adenomatous polyps and a very high cancer risk without intervention. Surveillance and prophylactic management are central to care.
A phase 1 study found MP0317, a FAP-targeting CD40 agonist, showed tumor-localized CD40 activation, a favorable safety profile, and immune remodeling in advanced solid tumors.
Recursion reported Q4 2025 financial results with $754 million in cash providing runway into early 2028. The company achieved clinical validation of its AI platform with REC-4881 showing meaningful polyp reductions in FAP patients and received its fifth Sanofi milestone payment. Full-year revenue reached $74.7 million while net loss widened to $644.8 million.
Tempest Therapeutics reported 2025 financial results showing $7.7 million in cash and highlighted clinical progress including 100% complete response rate in TPST-2003 CAR-T trial and multiple FDA designations for amezalpat in hepatocellular carcinoma. The company completed strategic CAR-T asset acquisition and plans Phase 2b registrational study for its lead program in 2026.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07199127 |
Duodenal Polyposis Classification in FAP |
RECRUITING | |
| NCT06911476 |
From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19 |
NOT_YET_RECRUITING | |
| NCT06782412 |
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types |
RECRUITING | PHASE2/PHASE3 |
| NCT06712095 |
Video Capsule Examination in Patients With Lynch Syndrome |
RECRUITING | NA |
| NCT06690970 |
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients |
RECRUITING | |
| NCT06640413 |
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors |
RECRUITING | PHASE1 |
| NCT06578637 |
Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis |
RECRUITING | NA |
| NCT06557590 |
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors |
RECRUITING | |
| NCT06387381 |
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease |
RECRUITING | EARLY_PHASE1 |
| NCT06189820 |
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases |
RECRUITING | PHASE2 |
